Keywords:
Hospitalization; Infants; Nirsevimab; Palivizumab; Prematurity; Respiratory syncytial virus; Seasonal trends
Abstract:
Respiratory syncytial virus contributes to significant global infant morbidity and mortality. We applied a previously developed statistical prediction model incorporating pre-pandemic RSV testing data and hospital admission data to estimate infant RSV-hospitalizations by birth month and prematurity, focused on infants aged <1 year.